Related Experiment Video
Updated: Apr 28, 2026

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
Published on: August 23, 2024
Interactions of PPAR α and GLUT4 in DOCA/salt-induced renal injury in mice
Igbe Ighodaro1, Omogbai Kelly Eric, Oyekan Adebayo
1Department of Pharmacology and Toxicology, Faculty of Pharmacy, University of Benin. igbe.ighodaro@uniben.edu.
Abstract:
Diminished insulin sensitivity is a characteristic feature of various pathological conditions such as hypertension and activation of peroxisome proliferator activated receptor α (PPARα) has been shown to enhance insulin resistance and reduce capacity for glucose uptake in muscles. The present study was designed to evaluate the interactions of PPARα and GLUT4 in a model of hypertensive renal injury by studying deoxycorticosterone acetate (DOCA)-salt induced hypertension in wild-type (WT) and PPARα knockout (KO) mice. PPARα WT and KO mice were uninephrectomized (UNx) and implanted subcutaneously DOCA and drank 1% sodium chloride/1% potassium chloride with or without a GLUT4 antagonist, indinavir (20 mg/kg/day, s.c) or PPARα ligand, fenofibrate (100 mg/kg/day, orally). DOCA/salt treatment increased urinary sodium excretion and urine volume (p<0.05) in PPARα KO mice compared to WT littermates. Indinavir increased proteinuria (p<0.01) in DOCA/salt-treated PPARα KO mice compared to WT littermates but did not affect heart and kidney weight index in DOCA/salt KO or WT-treated mice. Urinary sodium excretion (UNaV) and urine volume (UV) were increased by indinavir (p<0.01) and fenofibrate (p<0.05) in DOCA/salt-treated PPARα KO mice compared to WT mice. Urinary nitric oxide was greater in both fenofibrate (p<0.05) and indinavir-treated WT mice (p<0.05) compared to KO mice. These data suggest that in hypertensive nephropathy, GLUT4 probably exerts a renoprotective role that was enhanced with the activation of PPARα receptors by a mechanism that may be related to increased nitric oxide production.
Insights
In hypertensive kidney injury, glucose transporter type 4 (GLUT4) shows protective effects, especially when peroxisome proliferator activated receptor alpha (PPARα) is activated. This suggests a novel therapeutic target for kidney protection.
Area of Science:
- Nephrology
- Metabolic Syndrome
- Pharmacology
Background:
- Insulin resistance is linked to hypertension and reduced muscle glucose uptake.
- Peroxisome proliferator activated receptor alpha (PPARα) activation exacerbates insulin resistance.
- The interplay between PPARα and glucose transporter type 4 (GLUT4) in hypertensive renal injury is not fully understood.
Purpose of the Study:
- To investigate the roles of PPARα and GLUT4 in deoxycorticosterone acetate (DOCA)-salt induced hypertensive nephropathy.
- To evaluate the renoprotective potential of modulating PPARα and GLUT4 pathways.
Main Methods:
- Utilized wild-type (WT) and PPARα knockout (KO) mice subjected to DOCA-salt treatment.
- Administered indinavir (GLUT4 antagonist) or fenofibrate (PPARα ligand) to assess their effects.
- Measured urinary sodium excretion, urine volume, proteinuria, and nitric oxide levels.
Main Results:
- DOCA/salt treatment increased urinary sodium excretion and urine volume in PPARα KO mice compared to WT.
- Indinavir exacerbated proteinuria in DOCA/salt-treated PPARα KO mice.
- Both indinavir and fenofibrate increased urinary sodium excretion and urine volume in DOCA/salt-treated PPARα KO mice.
- Nitric oxide levels were higher in fenofibrate- and indinavir-treated WT mice compared to KO mice.
Conclusions:
- GLUT4 appears to play a renoprotective role in hypertensive nephropathy.
- PPARα activation enhances this protective effect, potentially via increased nitric oxide production.
- Targeting GLUT4 and PPARα pathways may offer therapeutic strategies for hypertensive kidney disease.
More Related Videos
10:31Comparative Proteomic Analysis of Whole Kidney, Medulla, and Cortical Tubules in Diabetic Pathogenesis of Kidney Injury in Mice
Published on: May 2, 2025
08:15Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease
Published on: May 10, 2024